EA201790785A1 - Производные тетрагидроизохинолина - Google Patents

Производные тетрагидроизохинолина

Info

Publication number
EA201790785A1
EA201790785A1 EA201790785A EA201790785A EA201790785A1 EA 201790785 A1 EA201790785 A1 EA 201790785A1 EA 201790785 A EA201790785 A EA 201790785A EA 201790785 A EA201790785 A EA 201790785A EA 201790785 A1 EA201790785 A1 EA 201790785A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
tetrahydroisoquinoline
pharmaceuticals
diseases
role
Prior art date
Application number
EA201790785A
Other languages
English (en)
Other versions
EA035544B1 (ru
Inventor
Анне Валаде
Эрик Жноф
Али Ате
Пьерр Бюрссан
Давид Скольц
Бенуа Матьё
Зара Санд
Original Assignee
Юсб Байофарма Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Байофарма Спрл filed Critical Юсб Байофарма Спрл
Publication of EA201790785A1 publication Critical patent/EA201790785A1/ru
Publication of EA035544B1 publication Critical patent/EA035544B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

В заявке описаны производные тетрагидроизохинолина формулы Iкоторые являются позитивными аллостерическими модуляторами D1 и поэтому полезны для применения в качестве фармацевтических средств, предназначенных для лечения заболеваний, в которых играют роль рецепторы D1.
EA201790785A 2014-10-08 2015-10-06 Производные тетрагидроизохинолина EA035544B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (2)

Publication Number Publication Date
EA201790785A1 true EA201790785A1 (ru) 2017-10-31
EA035544B1 EA035544B1 (ru) 2020-07-03

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790785A EA035544B1 (ru) 2014-10-08 2015-10-06 Производные тетрагидроизохинолина

Country Status (17)

Country Link
US (1) US10105359B2 (ru)
EP (1) EP3204359B1 (ru)
JP (1) JP6622299B2 (ru)
CN (1) CN107001278B (ru)
BR (1) BR112017007123B1 (ru)
CA (1) CA2963951C (ru)
CY (1) CY1123417T1 (ru)
DK (1) DK3204359T3 (ru)
EA (1) EA035544B1 (ru)
ES (1) ES2821821T3 (ru)
HR (1) HRP20201469T1 (ru)
HU (1) HUE050664T2 (ru)
LT (1) LT3204359T (ru)
PT (1) PT3204359T (ru)
RS (1) RS60933B1 (ru)
SI (1) SI3204359T1 (ru)
WO (1) WO2016055479A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180132629A (ko) * 2016-02-25 2018-12-12 아셰뉴론 에스아 글리코시다제 저해제
EP3442945B1 (en) * 2016-04-13 2020-07-08 UCB Biopharma SRL Tetrahydroisoquinoline derivatives
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
US20200369675A1 (en) 2017-12-01 2020-11-26 UCB Biopharma SRL Imaging Agents
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
CA3139571A1 (en) 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
CA3139622A1 (en) 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
WO2022076418A1 (en) * 2020-10-07 2022-04-14 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
JP2023551173A (ja) 2020-12-03 2023-12-07 ユーシービー バイオファルマ エスアールエル オクタヒドロイソキノリニル誘導体
EP4263522A1 (en) 2020-12-18 2023-10-25 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
CA3203281A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
KR20230121849A (ko) 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 D1 포지티브 알로스테릭 모듈레이터로서 치환된 테트라하이드로이소퀴놀린유도체
PE20240021A1 (es) * 2020-12-18 2024-01-04 UCB Biopharma SRL Dispersiones solidas amorfas
WO2022192231A1 (en) 2021-03-08 2022-09-15 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
EP4304577A1 (en) 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
EP1458714A1 (en) * 2001-12-19 2004-09-22 H. Lundbeck A/S 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
ES2342083T3 (es) * 2004-04-29 2010-07-01 Aventis Pharmaceuticals Inc. 3-piperidinilisocroman-5-oles como agonistas de dopamina.
CN101668746A (zh) * 2007-03-01 2010-03-10 詹森药业有限公司 作为组胺h3受体调节剂的四氢异喹啉化合物

Also Published As

Publication number Publication date
CY1123417T1 (el) 2021-12-31
HRP20201469T1 (hr) 2020-12-11
US20170304292A1 (en) 2017-10-26
PT3204359T (pt) 2020-09-24
CA2963951A1 (en) 2016-04-14
ES2821821T3 (es) 2021-04-27
EP3204359B1 (en) 2020-07-01
JP2017530185A (ja) 2017-10-12
CA2963951C (en) 2023-02-28
SI3204359T1 (sl) 2020-10-30
HUE050664T2 (hu) 2020-12-28
RS60933B1 (sr) 2020-11-30
BR112017007123B1 (pt) 2023-01-31
WO2016055479A1 (en) 2016-04-14
LT3204359T (lt) 2020-10-12
EP3204359A1 (en) 2017-08-16
CN107001278B (zh) 2020-11-24
DK3204359T3 (da) 2020-09-14
EA035544B1 (ru) 2020-07-03
US10105359B2 (en) 2018-10-23
BR112017007123A2 (pt) 2017-12-19
CN107001278A (zh) 2017-08-01
JP6622299B2 (ja) 2019-12-18

Similar Documents

Publication Publication Date Title
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201691582A1 (ru) Новые фармацевтические препараты
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
DK3258938T3 (da) Phenothiazinanaloger som mitokondrie terapeutiske midler
EA201892264A1 (ru) Производные тетрагидроизохинолина
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM